Desentum

Executive Summary

Desentum is a clinical-stage biopharmaceutical company headquartered in Helsinki, Finland, founded in 2014. The company specializes in developing novel allergen immunotherapy (AIT) products aimed at providing safer, more effective, and faster treatment options for common allergies, including birch pollen, grass pollen, and peanut. With its pipeline currently in Phase 2 clinical trials, Desentum leverages proprietary technology to potentially address the limitations of traditional allergy treatments, such as long treatment durations and safety concerns. The company is privately held and has not disclosed total funding or valuation. As a player in the growing allergy therapeutics market, Desentum's differentiated approach could position it for significant value creation if its clinical trials demonstrate competitive efficacy and safety profiles. However, the company remains in early to mid-stage development, with regulatory and commercialization risks ahead. Conviction in the company is tempered by the lack of detailed public clinical data and the competitive landscape, but the unmet need in allergy immunotherapy supports its potential.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for birch pollen AIT40% success
• Q1 2027Initiation of Phase 2 trial for peanut allergy AIT35% success
• Q2 2027Potential partnership or licensing deal for grass pollen AIT30% success